We are pleased to announce that Dr. Polymnia Louka of the Zanos Laboratory recently authored an informative article in a prominent Cypriot newspaper addressing the important relationship between depression and bone health.

In her article, Dr. Louka explains that depression is one of the most common psychiatric disorders in the modern world, affecting approximately 5% of the adult population. She discusses the established connection between depression and osteoporosis, highlighting how individuals with depression face increased risk of fractures and bone density loss, with women with major depressive disorder being particularly vulnerable.

Dr. Louka’s article describes how selective serotonin reuptake inhibitors (SSRIs) may influence bone mineral density, potentially increasing fracture risk by up to 40% in certain populations. This important public education piece emphasizes the need for healthcare providers to consider bone health when treating patients with depression.

Additionally, Dr. Louka discusses recent developments regarding ketamine as an innovative treatment for depression, particularly for patients who don’t respond to conventional therapies. The article suggests that addressing depression effectively might also benefit bone health, presenting a more holistic approach to patient care.

The publication represents Zanos Laboratory’s commitment to public education on the interactions between neurological conditions and physical health outcomes.

Dr. Louka’s researcher on ketamine and bone health is funded by a Marie Skłodowska-Curie co-fund scheme.